Biphasic Mesothelioma

If your pathology report says biphasic mesothelioma—or you are researching the diagnosis for someone in your family—this page is a place to start. Biphasic is one of the three principal mesothelioma histologic subtypes and contains both malignant epithelioid and malignant sarcomatoid components. For consistency across this site, we describe it as accounting for about 3 in 10 mesotheliomas overall, although reported proportions vary substantially by anatomical site, study population, specimen type, and how completely a tumor was sampled.¹

Evidence scope. Mesothelioma can arise in the pleura, peritoneum, pericardium, or tunica vaginalis—the membrane around a testicle. The same broad histologic subtypes are recognized across these sites, but the diagnostic, prognostic, and treatment evidence attached to them is not necessarily interchangeable. Most numerical outcomes and clinical-trial results discussed on this page come from diffuse pleural mesothelioma. Peritoneal mesothelioma has a smaller, separate evidence base and different treatment pathways. Primary pericardial mesothelioma and mesothelioma of the tunica vaginalis are exceptionally rare, so the available evidence comes mainly from registries, small series, and case reports. Unless stated otherwise, statistics on this page refer to pleural disease.^2–4

Biphasic histology is variable, but the component percentage is not a mathematical forecast. In a national cancer-registry (SEER) study of 1,183 patients with stage I–III pleural mesothelioma diagnosed from 2004 through 2010, before checkpoint immunotherapy became routine, median overall survival was 10 months for biphasic disease, compared with 14 months for epithelioid disease and 4 months for sarcomatoid disease.⁵ Because the study excluded stage IV disease, its medians are likely higher than they would be for all patients. Limited retrospective studies suggest that a larger sarcomatoid component—particularly when it predominates—may be associated with a less favorable prognosis. The estimate can differ between specimens and between pathologists, however, and no validated 15%, 25%, 30%, or 50% cutoff independently determines treatment or predicts one person's outcome.^6–8

Modern treatment evidence also requires careful labeling. In CheckMate 743, the pooled non-epithelioid subgroup—which combined biphasic and sarcomatoid tumors—had median overall survival of 18.1 months with nivolumab plus ipilimumab and 8.8 months with chemotherapy.⁹ That result materially changed treatment discussions for non-epithelioid pleural disease, but it is not a biphasic-only median and does not show whether a particular patient will respond.

You do not need to be an expert in pathology to make sense of your report. Most patients arrive here with a diagnosis they did not choose, a vocabulary they do not speak, and questions that have not been fully answered. The purpose of this page is to help you understand what the report says, what the component estimates can—and cannot—tell you about treatment and prognosis, and what questions may be worth raising with your medical team.

(Biphasic mesothelioma contains both malignant epithelioid tumor (left) and malignant sarcomatoid tumor (right). The two components may be sharply separated or intermingled. The pathology report estimates the share of each in the tissue examined; a larger sarcomatoid share is generally less favorable, but the estimate is one factor among many and does not by itself determine prognosis or treatment.^7,8)

What biphasic mesothelioma is

The term biphasic describes a mesothelioma containing two malignant microscopic patterns:

• Epithelioid areas, composed of relatively cohesive polygonal, cuboidal, or columnar cells that may form tubules, papillae, trabeculae, or solid sheets.
• Sarcomatoid areas, composed of elongated or spindle-shaped tumor cells growing in infiltrating sheets, fascicles, or other disorganized patterns.

The two components can be sharply separated, closely intermingled, or unevenly distributed across the tumor. Biphasic mesothelioma is treated as one mesothelial cancer with morphologic heterogeneity, not as a collision between an epithelioid cancer and an unrelated sarcoma. The pathologist must also determine that the spindle-cell area is genuinely malignant tumor rather than reactive fibrous or spindled mesothelial tissue beside an epithelioid mesothelioma.^2,7

Contemporary pathology guidance estimates that biphasic morphology accounts for approximately 15% to 30% of pleural mesotheliomas and 10% to 20% of peritoneal mesotheliomas.⁷ Those site-specific ranges help explain why a simple “3 in 10 overall” shorthand will not match every registry, hospital series, or biopsy cohort. In the registry study of stage I–III pleural cases described in the prognosis section, for example, biphasic tumors made up 12% of cases (148 of 1,183).⁵

At the population level, biphasic histology is associated with outcomes between those of epithelioid and sarcomatoid disease.^5,7 That general pattern does not tell doctors how far one person's cancer has spread or which treatment will work. Histology and component proportions do not replace staging, lymph-node evaluation, assessment of disease burden, performance status, organ function, or discussion of the patient's goals.

How biphasic pathology varies

Biphasic mesothelioma is especially vulnerable to sampling and interpretation differences. A pathologist can report only what is present in the material received, and a small piece of a heterogeneous tumor may not represent the whole. The component estimate should therefore be interpreted together with the specimen type, the amount of viable tissue, the number and location of samples, and the certainty that both components are malignant.^7,10,11

The WHO 10% rule applies differently to resections and biopsies

For a definitive resection specimen, the current WHO framework requires at least 10% epithelioid and at least 10% sarcomatoid morphology to classify a pleural tumor as biphasic. A resection specimen showing 95% epithelioid and 5% sarcomatoid morphology would ordinarily be classified by the dominant epithelioid subtype, although the minor sarcomatoid focus may still be described in the report.^2,7

For a biopsy specimen, there is no 10% minimum. If convincing malignant epithelioid and malignant sarcomatoid components are both present, the tumor can be diagnosed as biphasic even when one component occupies less than 10% of the sampled tissue. A thoracoscopic biopsy is still a biopsy for this purpose; the definitive-resection rule does not apply simply because the biopsy pieces are larger than a needle core.^2,7

The 10% figure is a classification convention, not a biological cliff. It does not mean that 9% sarcomatoid morphology is harmless or that 10% automatically changes treatment. In resected peritoneal mesothelioma, current diagnostic guidance recommends noting even focal sarcomatoid growth below 10% because limited evidence suggests it may still be clinically important.⁷

What the component percentages can—and cannot—tell you

Current guidance recommends reporting the estimated contribution of both components in biopsies and resections of biphasic mesothelioma.^6,7 The estimate is useful, but its limits should be explicit:

• More sarcomatoid morphology is generally unfavorable. Retrospective studies have linked a larger sarcomatoid component—or, equivalently, less epithelioid differentiation—to shorter survival on average.^7,8
• The evidence does not establish a treatment formula. No prospective trial validates 15%, 25%, 30%, 40%, or 50% as an automatic threshold for surgery, chemotherapy, immunotherapy, or an individual survival estimate.
• The number is not exact to the percentage point. In a study of expert thoracic pathologists, agreement was good when the sarcomatoid component was scored in broad 25% increments, but excellent case-level agreement occurred in only about one-quarter of tumors and was strongest at the extremes.^11,12
• A biopsy estimate is sample-specific. A later, larger specimen may contain a different proportion because it samples more of the tumor. An apparent “change” does not necessarily mean that one component transformed into the other during treatment.

For those reasons, a report of 70% epithelioid and 30% sarcomatoid should be read as an informed estimate from a particular specimen—not as proof that the tumor falls into a validated 30% treatment category.

Transitional and pleomorphic morphology

Transitional morphology consists of sheet-like growth by relatively cohesive, elongated but plump cells whose appearance lies between classic epithelioid and classic spindle-cell morphology. It should not be described literally as cells observed “turning into” sarcomatoid cells. Current WHO and diagnostic guidance regard transitional morphology as sarcomatoid for classification because its prognosis and molecular profile are closer to sarcomatoid disease. In an otherwise epithelioid tumor, a convincing transitional component can therefore support a biphasic diagnosis under the specimen-specific rules above.^2,7

Transitional morphology can be difficult to recognize reproducibly. Multi-institutional studies have found limited reproducibility for some borderline biphasic and transitional patterns, which is another reason that a report using this terminology may warrant specialist review before an irreversible treatment decision.^11,12

Pleomorphic morphology refers to markedly irregular or bizarre tumor cells. It is not a separate fourth mesothelioma subtype. The pathologist classifies it in the context of the tumor's remaining architecture and cytology and may describe it as an adverse feature within epithelioid, biphasic, or sarcomatoid disease.^2,7

Molecular and immune markers

Molecular and immunohistochemical findings can help establish that both areas are malignant mesothelial tumor, but they do not turn the component percentages into a treatment algorithm.

Finding	How it may help	Important limitation
BAP1 loss by immunohistochemistry	Loss in the spindle-cell component can support that the spindle cells are malignant rather than reactive.7,13 Recent data show strong concordance of the BAP1 pattern (lost versus retained) between the epithelioid and sarcomatoid components of biphasic mesothelioma.7	BAP1 loss is less sensitive in sarcomatoid morphology, and retained staining does not exclude mesothelioma. A tumor result does not establish whether an alteration is inherited.
MTAP loss by immunohistochemistry	Loss in a suspicious spindle-cell component can support malignancy and often reflects an underlying deletion involving the neighboring CDKN2A region.7	MTAP staining can be discordant between components, and retained staining does not exclude disease. It is an imperfect surrogate for CDKN2A deletion, and its use as one was validated mainly in pleural mesothelioma.
CDKN2A homozygous deletion by FISH	Deletion in the spindle-cell component strongly supports that it is malignant and can help distinguish true biphasic mesothelioma from epithelioid mesothelioma with reactive spindle-cell stroma.7	A negative result does not rule out mesothelioma, and the test does not by itself establish mesothelial lineage.
PD-L1 expression	It may provide descriptive or research information about the immune environment and may be relevant to a particular clinical-trial protocol.	PD-L1 does not establish the diagnosis, is not required for nivolumab plus ipilimumab, and is not a sufficiently reliable stand-alone predictor of response.6,9

If tumor testing shows BAP1 loss, the tumor result alone cannot determine whether an alteration was inherited; germline testing uses a non-tumor sample and a separate interpretive process. Tumor or germline BAP1 findings should not be used alone to prove or exclude the role of asbestos in an individual case.^6,7

How biphasic mesothelioma is diagnosed and classified

Diagnosing biphasic mesothelioma is an integrated process. The pathologist evaluates the morphology of both components, evidence that each component is malignant, invasion when it is represented, immunohistochemical evidence of mesothelial lineage, tests selected to exclude the relevant carcinomas and spindle-cell tumors, ancillary markers when reactive stroma remains a concern, and the clinical and imaging findings. No single stain proves a biphasic diagnosis.⁷

The sampling discussion below principally concerns pleural mesothelioma. Tumors arising in the peritoneum, pericardium, or tunica vaginalis may require different biopsy routes and site-specific differential diagnoses.

Tissue sampling

For a patient with suspected pleural mesothelioma who is being evaluated for anticancer treatment, thoracoscopic biopsy is generally preferred when it is medically feasible because it permits direct inspection and sampling from multiple abnormal pleural areas; the WHO recommends thoracoscopic evaluation with large biopsy specimens from different areas of the pleura for patients with persistent effusions.⁷ An image-guided core biopsy can be appropriate when thoracoscopy is not feasible or when imaging identifies a safe, representative target. The central question is whether the procedure yields enough viable, properly handled tissue to establish the diagnosis and assess heterogeneity without imposing unnecessary risk.

Biphasic disease is commonly underrecognized on initial biopsy because the two components may be located in different parts of the tumor. In a large study comparing presurgical biopsies with subsequent resections, identification of a biphasic pattern on biopsy had approximately 50% sensitivity and 96% specificity.¹⁰ In practical terms:

• When a biopsy convincingly shows both malignant components, the biphasic diagnosis is usually reliable.
• When a biopsy shows only epithelioid or only sarcomatoid disease, it cannot reliably exclude an unsampled second component.
• A later resection or larger specimen may therefore change the subtype without proving that the original pathologist made an error.

Pleural-fluid cytology has additional limitations because sarcomatoid tumor cells generally shed poorly. Fluid may help establish mesothelial malignancy in selected cases, but it ordinarily cannot exclude biphasic disease or provide a reliable whole-tumor component percentage.⁷

If the initial specimen is small or the subtype is uncertain, specialist review of the existing slides, unstained sections, and tissue blocks is often the appropriate next step before assuming that another invasive procedure is necessary. Repeat sampling may still be required when the tissue does not show invasion, contains too little viable tumor, or cannot resolve a clinically important differential diagnosis.

Immunohistochemistry: both components must be evaluated

The diagnostic panel should establish mesothelial differentiation and exclude the realistic alternatives in both morphologic areas. The two components need not stain identically.

Diagnostic question	Commonly considered tests	Important limitation
Does the epithelioid component support mesothelial lineage?	A panel commonly includes at least two mesothelial markers—such as calretinin, WT1, D2-40, or CK5/6—and at least two markers selected to exclude carcinoma, often including claudin-4 and organ-specific markers dictated by the differential diagnosis.	No single mesothelial marker is perfectly sensitive or specific. A mesothelial pattern establishes lineage; it does not by itself prove malignancy.
Are the spindle cells part of a malignant mesothelial tumor?	Broad-spectrum cytokeratins are often useful, with D2-40, calretinin, WT1, or CK5/6 considered according to the case. Morphology, invasion, and comparison with the epithelioid area are essential.	Traditional mesothelial markers are less sensitive in sarcomatoid areas: D2-40 and calretinin are each expressed in only about 50% to 60% of sarcomatoid mesotheliomas, staining may be focal, and each also stains roughly 20% to 25% of sarcomatoid lung carcinomas.7 Keratin positivity is useful but is not specific for mesothelioma.
Could the spindle cells represent another malignancy?	Depending on morphology and imaging, the panel may investigate sarcomatoid carcinoma, synovial sarcoma, solitary fibrous tumor, melanoma, vascular tumors, myogenic tumors, or another site-specific metastasis.	No fixed exclusion panel fits every case. Some sarcomatoid carcinomas lose broad epithelial markers, while synovial sarcoma and several other tumors may express cytokeratin.
Could the spindle cells be reactive rather than malignant?	The pathologist assesses atypia, growth pattern, necrosis, tissue invasion, keratin distribution, and ancillary BAP1, MTAP, or CDKN2A results in the spindle-cell population.	Reactive spindle-cell or mesothelial tissue can express cytokeratin. A diagnosis of biphasic mesothelioma should not rest on keratin positivity alone.

The stain result must be interpreted by where it appears, whether the stained cells are actually tumor, how strong and diffuse the staining is, and whether the complete pattern fits the morphology and clinical setting.

Ancillary testing when reactive spindle-cell stroma is a concern

One of the most important diagnostic pitfalls is epithelioid mesothelioma with a reactive spindle-cell mesothelial or fibrous response, which can mimic true biphasic mesothelioma. Current diagnostic guidance recommends interpreting BAP1, MTAP, and CDKN2A specifically within the suspicious spindle-cell population.⁷

• BAP1 or MTAP loss, or homozygous CDKN2A deletion, in the spindle-cell component supports that the component is malignant and therefore supports a biphasic diagnosis.
• If BAP1 or MTAP loss is confined to the epithelioid component while the spindle cells retain expression, the spindle-cell area should be called malignant only when it has unequivocal malignant morphology or other convincing evidence.
• Retained BAP1 or MTAP and negative CDKN2A FISH do not exclude biphasic mesothelioma.
• The tests are complementary, not interchangeable, and should not be used before mesothelial lineage and the relevant differential diagnosis have been considered.

Reporting the component percentages

For a biphasic diagnosis, current guidance recommends reporting the estimated percentage of the epithelioid component and the estimated percentage of the sarcomatoid component in both biopsy and resection specimens.^6,7 A useful report should also identify the specimen type so readers understand what the estimate represents.

On a biopsy, wording such as “approximately 70% epithelioid and 30% sarcomatoid in this specimen” is more accurate than implying that the complete tumor has been measured. On a resection, the larger amount of tissue allows a more representative estimate, but the number remains a pathologist's visual assessment and not an exact molecular measurement.

If a report confirms biphasic mesothelioma but omits the proportions, it is reasonable to ask whether the pathologist can provide an estimate. Sometimes the answer will be that the sample is too small, crushed, necrotic, or otherwise unrepresentative for a reliable percentage. That limitation should be stated rather than hidden, and care should not automatically be delayed or another biopsy performed solely to obtain a more precise number.

When expert pathology review is important

A second opinion from a pathologist with substantial mesothelioma and thoracic-pathology experience is particularly valuable when:

• The report uses uncertain language such as “mesothelioma with spindle-cell features,” “epithelioid mesothelioma with atypical stroma,” or “cannot exclude a biphasic component.”
• A small biopsy shows only one subtype, but imaging, later tissue, or the clinical course raises concern for a second component.
• The spindle-cell area may be reactive stroma rather than malignant sarcomatoid tumor.
• Transitional or pleomorphic morphology affects the classification.
• The component estimates are absent, appear unusually precise for a small sample, or differ substantially between reports.
• The immunohistochemical or molecular findings are discordant between the two areas.
• Sarcomatoid carcinoma, synovial sarcoma, another spindle-cell tumor, or a metastasis remains in the differential diagnosis.
• An irreversible or high-risk treatment decision is being considered.

A second opinion usually does not require the patient to travel. The original laboratory can send slides and tissue blocks to the consulting center, which then issues a separate report. Additional sampling may still be necessary when the material is inadequate, but review of the existing tissue is often the appropriate first step.

Want help organizing the questions raised by your pathology report? A member of our litigation team—not a medical screener—can review the document with you for case-intake purposes, help identify where terms such as biphasic, epithelioid, sarcomatoid, transitional, BAP1, MTAP, CDKN2A, or PD-L1 appear, and help you prepare questions for your medical team. We do not diagnose disease or recommend treatment. The conversation is free and creates no obligation.

Call 833-4-ASBESTOS or request a free case review.

What biphasic histology means for treatment

Unless stated otherwise, this section concerns diffuse pleural mesothelioma. Peritoneal mesothelioma follows a smaller, separate treatment literature, and pleural trial results should not automatically be transferred to peritoneal, pericardial, or tunica-vaginalis disease.

Biphasic pleural mesothelioma is generally grouped with sarcomatoid disease under the broader term non-epithelioid in treatment guidelines and clinical-trial subgroup analyses. The component estimate can add context, but it does not create a validated percentage-based treatment algorithm. Current evidence does not establish that 25%, 30%, 40%, or 50% sarcomatoid morphology automatically selects surgery, chemotherapy, immunotherapy, or a particular sequence.^6–9

Radical cytoreductive surgery generally is not recommended

Current ASCO guidance limits cytoreductive surgery to a narrow group of comprehensively staged patients with early-stage epithelioid pleural mesothelioma and favorable characteristics. Biphasic histology therefore generally weighs against radical tumor-removing surgery, even when the sampled tumor is described as predominantly epithelioid.⁶

MARS2 found worse overall outcomes with extended pleurectomy/decortication plus chemotherapy than with chemotherapy alone in the randomized population, together with more serious adverse events and worse quality of life. The trial did not establish a biphasic subgroup that benefited from surgery, and no prospective evidence has validated a sarcomatoid-percentage cutoff that identifies one.^6,14

That conclusion does not rule out procedures performed primarily to improve comfort or function. Drainage of a pleural effusion, placement of an indwelling pleural catheter, pleurodesis, or another symptom-directed procedure may be appropriate even when pleurectomy/decortication or extrapleural pneumonectomy is not.

Checkpoint-containing systemic therapy generally moves to the center of the discussion

For previously untreated, unresectable non-epithelioid pleural mesothelioma without a medical contraindication to checkpoint immunotherapy, current ASCO guidance generally favors nivolumab plus ipilimumab as the first-line approach.⁶ The pivotal evidence is the pooled non-epithelioid CheckMate 743 result described earlier on this page—18.1 months with nivolumab plus ipilimumab versus 8.8 months with chemotherapy.⁹

The result needs several qualifications:

• Biphasic and sarcomatoid tumors were analyzed together, so it is not a biphasic-only estimate.
• The trial did not validate a particular component percentage as the point at which immunotherapy begins to work.
• A group-level survival advantage cannot predict whether one patient's tumor will respond or whether treatment will have to stop because of toxicity.

ASCO also lists pembrolizumab with platinum-pemetrexed chemotherapy as a first-line option for either epithelioid or non-epithelioid disease. Its first-line recommendation for platinum-pemetrexed chemotherapy, with or without bevacizumab, is framed for epithelioid histology; in non-epithelioid disease, chemotherapy is generally discussed when checkpoint immunotherapy cannot be given or after it.⁶ No randomized trial directly compares every available approach. The reason immunotherapy is unsuitable also matters: a pembrolizumab-containing regimen is not an alternative when the contraindication applies to checkpoint immunotherapy as a class.

What the component estimate does—and does not—decide

A larger sarcomatoid component can support a more cautious prognosis discussion, and a specialist may consider the estimate alongside the tumor's other features. But the number should not be used alone to decide treatment. Important factors include:

• Whether the percentage comes from a small biopsy or a more representative specimen
• Stage, lymph-node involvement, and overall disease burden
• Symptoms and the need for relatively prompt tumor shrinkage
• Performance status, kidney and liver function, autoimmune disease, transplant history, and other medical conditions
• Prior treatment, toxicity preferences, treatment logistics, and the patient's goals
• Clinical-trial availability

PD-L1 expression is not required for nivolumab plus ipilimumab and is not a sufficiently reliable stand-alone selection test. Likewise, BAP1, MTAP, or CDKN2A findings may clarify the diagnosis or affect a particular trial's eligibility criteria, but they do not independently choose a standard regimen.^6,7,9

A specialty consultation can be particularly useful when the pathology is uncertain, major medical conditions complicate systemic treatment, or a clinical trial may be available. Much of the day-to-day care can often be delivered locally with a specialty team advising on the overall plan.

For details about drug combinations, dosing, adverse effects, later-line treatment, radiation, tumor treating fields, clinical trials, symptom management, and costs, see our pleural mesothelioma treatment page.

Prognosis and outcomes for biphasic mesothelioma

Biphasic mesothelioma is associated with outcomes between epithelioid and sarcomatoid disease on average. That is useful population-level information, but it does not turn a pathology percentage into an individual timeline. Prognosis also depends on anatomical site, stage, lymph-node involvement, disease burden, overall health, available treatment, and how the cancer responds.

As explained at the beginning of this page, most numerical evidence below concerns diffuse pleural mesothelioma. Peritoneal mesothelioma has a separate evidence base, and primary pericardial and tunica-vaginalis mesotheliomas are too rare for equally precise estimates.

Historical population data provide context—not a present-day prediction

In the SEER analysis of 1,183 patients with stage I–III pleural mesothelioma diagnosed from 2004 through 2010, median overall survival was 10 months for biphasic disease, compared with 14 months for epithelioid disease and 4 months for sarcomatoid disease. Among the 416 patients analyzed after cancer-directed surgery, biphasic histology was associated with a higher risk of death than epithelioid histology after adjustment for other recorded factors (hazard ratio 1.62).⁵

Those data are historical. The analysis excluded stage IV disease, so its medians are likely higher than they would be for all patients; it included patients with different ages, health conditions, and treatments; it predated routine first-line checkpoint immunotherapy; and it cannot fully account for every factor that influenced treatment selection. The 10-month median should not be presented as the expected outcome for every person diagnosed today.

Component proportions add information, but not a precise forecast

Retrospective studies support the broad conclusion that tumors with more epithelioid differentiation tend to have more favorable outcomes than tumors with a larger sarcomatoid component.^7,8 The evidence is not precise enough to say that a 70/30 tumor has one median and a 60/40 tumor has another.

Three limitations are especially important:

1. The estimate may come from a biopsy that samples only a small and uneven part of the tumor.
2. Expert pathologists can disagree when borderline or transitional areas are assigned a percentage.^11,12
3. No prospective treatment trial has validated a specific component cutoff as an individual survival predictor.

For those reasons, the most defensible use of the percentage is as one prognostic factor among many—particularly informative at the extremes, but not a substitute for stage, disease burden, overall health, or actual treatment response.

Modern trial results are encouraging—but still pooled

CheckMate 743 materially changed expectations for unresectable non-epithelioid pleural mesothelioma. The pooled biphasic-and-sarcomatoid subgroup had median overall survival of 18.1 months with nivolumab plus ipilimumab and 8.8 months with chemotherapy.⁹ At five years, the corresponding survival rates were 12% and 1%.¹⁵

Those figures should not be relabeled as a biphasic median or used to promise multi-year survival. The trial enrolled patients with previously untreated unresectable pleural disease and relatively good performance status, and it did not provide a reliable separate estimate for biphasic tumors. A patient with peritoneal disease, substantial comorbidity, poor functional status, or another clinical situation outside the trial population may have a different outlook.

The long-term result supports a narrower conclusion: modern immunotherapy has made durable multi-year disease control possible for a minority of patients with non-epithelioid pleural mesothelioma. It does not identify in advance which biphasic patients will experience that outcome.

Factors that shape an individual prognosis

Important sources of variation include:

• Anatomical site. Pleural and peritoneal mesothelioma follow different staging, treatment, and outcome literature. Results from one site should not be applied automatically to another.
• Stage, lymph nodes, and disease burden. Pleural mesothelioma should be staged under the current ninth-edition framework. Stage is separate from histology and remains important even when the component estimate is known.¹⁶
• Performance status and organ function. These affect baseline prognosis and which treatments can be given safely.
• Representativeness of the specimen. A small biopsy can underrepresent either component, and a later specimen may produce a different estimate without proving that the biology suddenly changed.
• Treatment received and actual response. Some patients obtain prolonged control from immunotherapy or another systemic approach; others do not respond or must stop treatment because of toxicity.
• Patient goals and supportive care. Symptom control, palliative care, and practical support can be integrated from diagnosis and do not require stopping cancer-directed treatment.

A specialist review can help clarify difficult pathology or treatment questions, but it should not be described as guaranteeing a better outcome. It also does not mean that every infusion, scan, or follow-up visit must occur far from home.

Long-term survival

Long-term survival remains uncommon, but it is not impossible. The best available randomized long-term data concern the pooled non-epithelioid group rather than biphasic disease alone.¹⁵ A patient-facing discussion should therefore present multi-year control as a possibility for a minority—not as an expected result—and should avoid using one component percentage to determine whether that possibility applies.

How biphasic pathology can shape the questions a family asks

The following is a fictional composite. It illustrates a decision process, not a predicted medical or legal outcome.

Howard, 72, served in the Navy as a boiler technician and later worked as a maintenance electrician at a chemical plant. Decades afterward, imaging for recurrent shortness of breath showed pleural thickening and a right-sided effusion. A needle-core biopsy was initially reported as epithelioid mesothelioma with an atypical spindle-cell response.

Before a major treatment decision, the existing slides and tissue block were sent to a pathologist with substantial mesothelioma experience. The reviewer concluded that some spindle-cell areas were malignant rather than merely reactive. Broad-spectrum cytokeratin supported the spindle-cell population, and homozygous CDKN2A deletion was demonstrated in that component. The integrated diagnosis was biphasic pleural mesothelioma, estimated at approximately 70% epithelioid and 30% sarcomatoid in the biopsy material. The report also explained that a small specimen might not represent the complete tumor.

The revised diagnosis changed the questions, but it did not create a 30% treatment rule. Howard's multidisciplinary team reviewed current staging, lymph nodes, disease burden, cardiopulmonary fitness, and the randomized surgery evidence. They explained that current guidance generally weighs against radical cytoreductive surgery for biphasic disease, even when the biopsy is predominantly epithelioid. They then discussed nivolumab plus ipilimumab, pembrolizumab plus platinum-pemetrexed, chemotherapy without immunotherapy if medically necessary, clinical trials, and early symptom-directed care. PD-L1 was reported but was not treated as a yes-or-no test for any one regimen.

On a separate track, Howard's family began documenting his Navy duties, civilian worksites, contractors, equipment, products, and possible household exposures. That information allowed counsel to investigate whether any trust claims, civil claims, veterans benefits, or other programs might apply. The medical team made the treatment decisions; the legal review addressed exposure evidence, deadlines, program rules, possible liens or offsets, and the practical needs created by care. Neither the pathology percentage nor the example guarantees a treatment response, a claim, or a particular recovery.

Potential sources of compensation and benefits

Biphasic histology ordinarily does not determine whether a person qualifies for a lawsuit, asbestos bankruptcy trust claim, workers' compensation system, or public-benefit program. Eligibility depends on the diagnosis, exposure evidence, responsible entities, employment or service history, jurisdiction, program rules, and filing deadlines.

Potential routes can include:

• Asbestos bankruptcy trusts. A trust may accept a claim when its medical and exposure criteria are met. Different trusts have different product, worksite, occupation, timing, and documentation requirements. How asbestos trust claims work.
• Civil claims against legally responsible entities. Depending on the evidence and governing law, potential defendants may include solvent manufacturers, suppliers, contractors, premises owners, or other entities connected to an exposure. How product-liability claims work.
• Workers' compensation and federal employment systems. The Longshore and Harbor Workers' Compensation Act generally covers maritime workers injured on navigable waters or adjoining areas such as docks and shipyards. FECA applies to eligible federal employees with work-related injury or disease; working at a federal facility does not by itself establish FECA coverage.^17,18
• Disability and veterans benefits. Social Security Disability Insurance requires a qualifying disability and sufficient covered work history. VA disability compensation requires evidence connecting the condition to military service, including service-related asbestos exposure when applicable.^19,20 Social Security lists pleural, peritoneal, and pericardial mesothelioma as Compassionate Allowances conditions, which speeds up review of a disability claim but does not change the work-credit or other eligibility rules. The list also names sarcomatoid and desmoplastic mesothelioma separately; biphasic disease has no entry of its own and is covered through the site-based entries.²¹

These routes should not be described as automatically independent. Trust submissions, civil claims, workers' compensation, health insurance, Medicare or Medicaid, and benefit programs may involve disclosure duties, liens, reimbursement rights, offsets or setoffs, releases, exclusivity rules, or other coordination issues. A case-specific review is needed before saying that several routes can all proceed or that one recovery cannot affect another.

The component percentage does not create, extend, or shorten a legal filing period. A more aggressive clinical course may make it practically important to preserve the patient's account of worksites, products, duties, coworkers, and service history promptly, but the governing law and program rules determine the deadline.

References

1. American Cancer Society. Mesothelioma. Last revised February 3, 2026. Accessed October 27, 2026. https://www.cancer.org/cancer/types/malignant-mesothelioma.html
2. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608-622. doi:10.1016/j.jtho.2021.12.014.
3. Klebe S, Judge M, Brcic L, et al. Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2024;84(4):633-645. doi:10.1111/his.15106.
4. Marinaccio A, Consonni D, Mensi C, et al.; ReNaM Working Group. Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case-control study and epidemiological remarks. Scand J Work Environ Health. 2020;46(6):609-617. doi:10.5271/sjweh.3895.
5. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. doi:10.1016/j.jss.2015.01.043.
6. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of pleural mesothelioma: ASCO guideline update. J Clin Oncol. 2025;43(8):1006-1038. doi:10.1200/JCO-24-02425.
7. Husain AN, Chapel DB, Attanoos R, et al. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251-1271. doi:10.5858/arpa.2023-0304-RA.
8. Vigneswaran WT, Kircheva DY, Ananthanarayanan V, et al. Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma. Ann Thorac Surg. 2017;103(3):962-966. doi:10.1016/j.athoracsur.2016.08.063.
9. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8.
10. Chirieac LR, Hung YP, Foo WC, et al. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer. 2019;125(23):4164-4171. doi:10.1002/cncr.32416.
11. Dacic S, Le Stang N, Husain A, et al. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. Mod Pathol. 2020;33(2):255-262. doi:10.1038/s41379-019-0320-y.
12. Galateau Salle F, Le Stang N, Nicholson AG, et al. New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the International Mesothelioma Panel from the MESOPATH Reference Center. J Thorac Oncol. 2018;13(8):1189-1203. doi:10.1016/j.jtho.2018.04.023.
13. Righi L, Duregon E, Vatrano S, et al. BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study. J Thorac Oncol. 2016;11(11):2006-2017. doi:10.1016/j.jtho.2016.06.020.
14. Lim E, Waller D, Lau K, et al.; MARS 2 Investigators. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457-466. doi:10.1016/S2213-2600(24)00119-X.
15. Scherpereel A, Baas P, Nowak AK, et al. Five-year clinical outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma in CheckMate 743. J Clin Oncol. 2026;44(9):742-749. doi:10.1200/JCO-25-01328. Errata: J Clin Oncol. 2026;44(19):1852, doi:10.1200/JCO-26-01289; and 2026;44(29):2878, doi:10.1200/JCO-26-02181.
16. Nowak AK, Giroux DJ, Eisele M, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: proposal for revision of the TNM stage groupings in the forthcoming (ninth) edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2024;19(9):1339-1351. doi:10.1016/j.jtho.2024.05.002.
17. U.S. Department of Labor, Office of Workers' Compensation Programs. Longshore and Harbor Workers' Compensation Act frequently asked questions. Accessed October 27, 2026. https://www.dol.gov/agencies/owcp/dlhwc/FAQ/lsfaqs
18. U.S. Department of Labor, Office of Workers' Compensation Programs. Federal Employees' Compensation Program. Accessed October 27, 2026. https://www.dol.gov/agencies/owcp/FECA
19. Social Security Administration. Who can get Disability. Accessed October 27, 2026. https://www.ssa.gov/disability/eligibility
20. U.S. Department of Veterans Affairs. Veterans asbestos exposure. Accessed October 27, 2026. https://www.va.gov/disability/eligibility/hazardous-materials-exposure/asbestos/
21. Social Security Administration. Compassionate Allowances (CAL) conditions. Updated August 10, 2026. Accessed October 27, 2026. https://www.ssa.gov/compassionateallowances/conditions.htm
22. Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789.
23. Central News Agency (Taiwan). 北極星藥業撤惡性間皮瘤藥證申請 調整美子公司人力 [Polaris Pharmaceuticals withdraws malignant mesothelioma drug license application]. May 25, 2026. Accessed October 29, 2026. https://www.cna.com.tw/news/afe/202605250314.aspx